Some improvement‡ in their ability to be active and an improvement in their symptoms
OR
More improvement‡ in their ability to be active and no worsening of their symptoms
Could CAMZYOS be right for you?
Has the information on this website motivated you to speak to your cardiologist about CAMZYOS?
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.
Finding Hope,
Making a Change
Dani, a patient living with symptomatic obstructive HCM, and her daughter Kassidy were compensated for their time. Individual results may vary.
Since taking CAMZYOS, my symptoms have been improving and things have changed for the better.
—Dani
Dani was diagnosed with obstructive HCM in her 50s. It started with symptoms like shortness of breath, or fatigue while doing simple things like shopping or walking. When she was diagnosed, Dani tried an oral medication, but her obstruction didn’t improve and she eventually needed a myectomy, a type of open heart surgery. Despite this, and having tried a few other treatment options, her symptoms did not improve. Then, her doctor prescribed CAMZYOS.
Individual results may vary.
Clinical Study Results
In a clinical study, CAMZYOS improved symptoms* and the ability to be active.†
A 30-week clinical study of 251 people compared two groups of adults with symptomatic obstructive HCM. One group (123 people) took CAMZYOS and the other group (128 people) took a placebo. All participants who enrolled in the study were symptomatic (73% had NYHA Class II symptoms and 27% had Class III symptoms*). Though it wasn’t a requirement of the study, most of the participants (231) remained on their previous medication, a beta blocker or calcium channel blocker.
WHAT THE STUDY
RESULTS SHOWED‡
The study first looked at how many people experienced either:
Results showed that more people taking CAMZYOS achieved this outcome (37%, 45/123)
compared with those taking placebo (17%, 22/128).
*Symptoms were measured using the New York Heart Association (NYHA) classification.
†The ability to be active was determined by measuring peak oxygen consumption or pVO2, which is the maximum amount of oxygen the body uses during exercise. This was measured during exercise testing on a bicycle or treadmill.
‡Some improvement=improved pVO2, by at least 1.5 mL/kg/min. More improvement=improved pVO2 by at least 3.0 mL/kg/min.
The study then looked at other data and measurements referred to as secondary endpoints.
Compared to people taking placebo, people taking CAMZYOS were assessed in the following areas: change in symptoms, obstruction, and patient-reported outcomes.
~2 out of 3 people taking CAMZYOS
had their symptoms improve
What the data showed: Of those taking CAMZYOS, 65% (80/123) improved by one or more NYHA class compared with 31% (40/128) of those taking a placebo.
How was this measured? Symptom improvement was defined as a lower NYHA class at the end of the study.
Obstruction to blood flow within the heart decreased 4x more with CAMZYOS when compared with placebo
What the data showed: People who took CAMZYOS had an average decrease in their LVOT gradient of 47 mmHg (started at 86 mmHg and went down to 38 mmHg), and people who took a placebo had an average decrease of 10 mmHg (started at 84 mmHg and went down to 73 mmHg).
How was this measured? At the beginning and end of the study, the obstruction in people’s hearts was measured with an echocardiogram after they exercised. This was done to find out how much blood was able to pump out of the heart in millimeters of mercury, or mmHg. Doctors call this measurement the left ventricular outflow tract, or LVOT, gradient. A lower LVOT gradient means there is less obstruction in the heart.
Why is thisimportant?
3x greater improvement
in symptom burden and
physical limitations
What the data showed: From when they started the study to when it ended, people taking CAMZYOS reported an average change in score of +14, and those who took placebo reported an average change in score of +4. The average baseline score was 71 for patients starting the trial.
How was this measured? How much people were bothered by their symptoms and experienced physical limitations was assessed using the Kansas City Cardiomyopathy Questionnaire (23-item version)–Clinical Summary Score (KCCQ-CSS). Higher scores represent better health status.
3x greater improvement
in shortness of breath
What the data showed: From when they started the study to when it ended, people taking CAMZYOS reported an average change in score of -3 and those who took placebo reported an average change in score of -1. The average baseline score was 5 for patients starting the trial.
How was this measured? The frequency and severity of people’s shortness of breath was assessed using the Hypertrophic Cardiomyopathy Symptom Questionnaire–Shortness-of-Breath subscore (HCMSQ-SoB). Lower scores represent less shortness of breath.
In the second study,
CAMZYOS reduced the amount of patients who were eligible for, or who chose to undergo, surgery at 16 weeks (avoiding surgery)
A 16-week study of 112 people compared two groups of adults with symptomatic obstructive HCM. One group (56 people) took CAMZYOS while the other group (56 people) took a placebo. When the study started, everyone had symptoms. Some (7%) had moderate symptoms (NYHA Class II), but most (93%) had severe symptoms (NYHA Class III or IV). Everyone’s obstructive HCM was so advanced that they were eligible for heart surgery.
WHAT THE STUDY RESULTS SHOWED
The study looked at how many people either:
Remained eligible for surgery at Week 16
OR
Decided to proceed with surgery prior to or at Week 16
Results showed that CAMZYOS reduced the proportion of patients who were eligible for, or who chose to undergo, surgery. 18% of people taking CAMZYOS (~1 out of 5) and 77% of people taking placebo (~4 out of 5) remained eligible for surgery at 16 weeks or chose to undergo surgery prior to or at Week 16. Two people in each group decided to have surgery.
4 out of 5 people who took CAMZYOS experienced improvements in their symptomatic obstructive HCM to the point that they were able to avoid surgery§ at 16 weeks
vs 1 out of 5 people who took placebo
§No longer eligible and did not choose to undergo surgery at Week 16.
Most people in this study (95%) were also taking additional treatments for their HCM such as a beta blocker, calcium channel blocker, disopyramide, or a combination of these.
CAMZYOS will not work for everyone.
Individual results may vary.
Side Effects
If you and your doctor are considering CAMZYOS, it’s important to know the answers to these questions:
What are the serious side effects of CAMZYOS?
A serious side effect is a side effect that can sometimes be life-threatening and lead to death.
CAMZYOS may cause serious side effects, including heart failure (a condition where the heart cannot pump with enough force).
Get medical help right away if you experience new or worsening symptoms, including:
- Shortness of breath
- Chest pain
- Fatigue
- Racing heart (palpitations)
- Leg swelling
- Rapid weight gain
What are the most common side effects?
The most common side effects of CAMZYOS include dizziness and fainting (syncope).
- Tell your healthcare provider if you have any side effect that bothers you or that does not go away
- These are not all of the possible side effects of CAMZYOS
- Talk to your healthcare provider for more information about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Bristol Myers Squibb at 1-800-721-5072
For more information, please see the U.S. Full Prescribing Information, including Boxed WARNING and Medication Guide for CAMZYOS. Talk to your healthcare provider for more information about this medication.
Get Tips for Talkingwith Your Doctor
